Clinical trial
The Relationship of Defeverscence and Itraconazole Plasma Level Using Sporanox IV as an Empiric Therapy in Immunocompromised Patients Who Have Been Treated With Sporanox Oral Solution as Prophylaxis
NCT01021683 is registered in ClinicalTrials.gov with Janssen Korea, Ltd., Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Relationship of Defeverscence and Itraconazole Plasma Level Using Sporanox IV as an Empiric Therapy in Immunocompromised Patients Who Have Been Treated With Sporanox Oral Solution as Prophylaxis
- Lead sponsor
- Janssen Korea, Ltd., Korea
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- July 31, 2010
- Enrollment
- 203 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.